141 related articles for article (PubMed ID: 9083515)
21. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.
Miettinen M; Kärkkäinen P
Virchows Arch; 1996 Nov; 429(4-5):213-9. PubMed ID: 8972756
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid.
Soares P; Cameselle-Teijeiro J; Sobrinho-Simões M
Histopathology; 1994 Mar; 24(3):205-10. PubMed ID: 8200621
[TBL] [Abstract][Full Text] [Related]
23. Bcl-2 and p53 expression in insular and in well-differentiated thyroid carcinomas with an insular pattern.
Peştereli HE; Oğüş M; Oren N; Karpuzoğlu G; Kerpuzoğlu T
Endocr Pathol; 2001; 12(3):301-5. PubMed ID: 11740051
[TBL] [Abstract][Full Text] [Related]
24. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
[TBL] [Abstract][Full Text] [Related]
25. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.
Farid P; Gomb SZ; Péter I; Szende B
Neoplasma; 2001; 48(4):299-301. PubMed ID: 11712682
[TBL] [Abstract][Full Text] [Related]
26. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
27. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL.
Lee ML; Chen GG; Vlantis AC; Tse GM; Leung BC; van Hasselt CA
Cancer J; 2005; 11(2):113-21. PubMed ID: 15969986
[TBL] [Abstract][Full Text] [Related]
28. Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours.
Cvejic D; Selemetjev S; Savin S; Paunovic I; Tatic S
Eur J Histochem; 2009; 53(2):65-71. PubMed ID: 19683979
[TBL] [Abstract][Full Text] [Related]
29. c-Met expression of thyroid tissue with special reference to papillary carcinoma.
Oyama T; Ichimura E; Sano T; Kashiwabara K; Fukuda T; Nakajima T
Pathol Int; 1998 Oct; 48(10):763-8. PubMed ID: 9788259
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression.
Moore D; Ohene-Fianko D; Garcia B; Chakrabarti S
Histopathology; 1998 Jan; 32(1):35-42. PubMed ID: 9522214
[TBL] [Abstract][Full Text] [Related]
32. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
[TBL] [Abstract][Full Text] [Related]
33. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas.
Krajewska M; Moss SF; Krajewski S; Song K; Holt PR; Reed JC
Cancer Res; 1996 May; 56(10):2422-7. PubMed ID: 8625322
[TBL] [Abstract][Full Text] [Related]
34. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
35. Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma.
Okayasu I; Saegusa M; Fujiwara M; Hara Y; Rose NR
J Cancer Res Clin Oncol; 1995; 121(12):746-52. PubMed ID: 7499446
[TBL] [Abstract][Full Text] [Related]
36. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Stassi G; Todaro M; Zerilli M; Ricci-Vitiani L; Di Liberto D; Patti M; Florena A; Di Gaudio F; Di Gesù G; De Maria R
Cancer Res; 2003 Oct; 63(20):6784-90. PubMed ID: 14583474
[TBL] [Abstract][Full Text] [Related]
37. Decreased expression of p107 is correlated with anaplastic transformation in papillary carcinoma of the thyroid.
Ito Y; Yoshida H; Tomoda C; Uruno T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
Anticancer Res; 2003; 23(5A):3819-24. PubMed ID: 14666683
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity.
Jordan RC; Catzavelos GC; Barrett AW; Speight PM
Eur J Cancer B Oral Oncol; 1996 Nov; 32B(6):394-400. PubMed ID: 9039223
[TBL] [Abstract][Full Text] [Related]
39. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
40. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
Bossowski A; Czarnocka B; Bardadin K; Urban M; Niedziela M; Dadan J
Horm Res; 2008; 70(3):155-64. PubMed ID: 18663316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
